Methods for the derivation and use of cardiomyocytes from human pluripotent stem cells.
Methods for the derivation and use of cardiomyocytes from human pluripotent stem cells.
复制标题
DOI：
10.1007/978-1-61779-201-4_31
复制
发表时间：
2011
期刊：
影响因子：
--
通讯作者：
Laflamme, Michael A
中科院分区：
文献类型：
--
作者：
Zhu, Wei-Zhong;Van Biber, Benjamin;Laflamme, Michael A
源自胚胎干细胞（ESCs）的人类心肌细胞的可用性引起了相当大的兴奋，因为这些细胞是研究心肌发育的优秀模型系统，并可能最终应用于基于细胞的心脏修复。从相关的诱导多能干细胞（iPSC）衍生的心肌细胞具有类似的特性，但也提供了患者特异性疾病建模和细胞治疗的前景。不幸的是，历史上从多能干细胞产生心肌细胞的方法是不可靠的，并且通常导致低心脏纯度的制备（通常<1%心肌细胞）。我们在这里详细介绍了最近报道的定向心脏分化方案的方法，该方案涉及连续应用已知参与早期胚胎心脏发育的两种生长因子：激活素A和骨形态发生蛋白-4（BMP-4）。该方案可靠地产生30-60%心肌细胞的制备物，然后可以使用简单的物理方法将其进一步富集至>90%心肌细胞。
The availability of human cardiomyocytes derived from embryonic stem cells (ESCs) has generated considerable excitement, as these cells are an excellent model system for studying myocardial development and may have eventual application in cell-based cardiac repair. Cardiomyocytes derived from the related induced pluripotent stem cells (iPSCs) have similar properties but also offer the prospects of patient-specific disease modeling and cell therapies. Unfortunately, the methods by which cardiomyocytes have been historically generated from pluripotent stem cells are unreliable and typically result in preparations of low cardiac purity (typically <1% cardiomyocytes). We detail here the methods for a recently reported directed cardiac differentiation protocol, which involves the serial application of two growth factors known to be involved in early embryonic heart development, activin A and bone morphogenetic protein-4 (BMP-4). This protocol reliably yields preparations of 30-60% cardiomyocytes, which can then be further enriched to >90% cardiomyocytes using straightforward physical methods.